The poster, titled “Outer Retina-Choroid en ... Ophthalmology of MERIT. About the Presentation: • Title: “Outer Retina-Choroid en face Image, ORC™: Characterization of A Novel Morphologic ...

Gain Therapeutics' lead drug candidate, GT-02287, is in clinical development for the treatment of Parkinson's disease (PD) with or without a GBA1 mutation. The orally administered, brain-penetrant ...

30th World Congress on Parkinson's Disease and Related Disorders, being held May 7th-10th in New York City, NY. Details of the oral and poster presentation are as follows: ...

Entopsis Inc., and Genetics Institute of America has been accepted for presentation at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place May 30–June 3 ...

Details of the oral and poster presentation are as follows: Presentation Title: GT-02287, A Clinical-stage Allosteric GCase Modulator For The Treatment Of Parkinson’s Disease, Protects Dopaminergic ...

("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in ...

Flap endonuclease 1 (FEN1) is a structure-specific di-magnesium metallonuclease that cleaves 5' DNA flaps during replication and repair. FEN1 is an attractive target for development of anticancer ...

Phase 1a dose-escalation study data update: treatment with NXP900 resulted in exposure levels leading to robust pharmacodynamic responses across a range of tolerated doses; NXP900 has an ...

Microsoft is trying to simplify AI sales, according to slides from an internal presentation. The current approach slowed sales, confused customers, and affected cost and quality, insiders say.

ClearB Therapeutics, Inc., a company developing therapeutic vaccines designed to drive a functional cure for Hepatitis B, announced today that an abstract will be presented as a poster at the ...